Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

JW Therapeutics Raises $100 Million to Support CAR-T Portfolio

publication date: Jun 10, 2020

JW Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company, has completed a $100 million Series B round financing co-led by CPE and Mirae Asset. JW is a joint venture formed in 2016 by WuXi AppTec and Juno Therapeutics of Seattle that was formed to bring Juno's immunoncology drugs to China. The company's lead product, a CAR-T therapy targeting CD19 for non-Hodgkin's Lymphoma, has started Phase II trials in China. More details....

Share this with colleagues:




This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China